報價延遲最少15分鐘:2025/07/10 23:12 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.14/-1.00
|
|
企業價值
12.79M
|
| 資產負債 |
|
每股賬面淨值
-0.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
58.00K
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/10 23:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). |